vTv Therapeutics (Nasdaq: VTVT) reported third-quarter financial results and completed enrollment of 166 participants in its Phase 3 CATT1 trial. The study evaluates cadisegliatin alongside insulin for type 1 diabetes; vTv expects topline results in mid 2027. The first participant was also randomized in the Phase 2a Hybrid CATT1 study for people using hybrid closed-loop insulin delivery systems. HPPD received FDA Orphan Drug Designation for sickle cell disease.Third-quarter net loss attributable to shareholders widened to $11.620 million from $8.698 million a year earlier, while loss per share narrowed to $0.94 from $1.08. Cash totaled $77.164 million at September 30, versus $88.932 million at December 31, 2025. vTv expects its cash to fund operations well through the anticipated CATT1 readout. Nine-month revenue was $36.839 million, versus none a year earlier.

A través de la Resolución 200/2026, con fecha 15 de octubre de 2026, la Secretaría de Agricultura, Ganadería y Pesca aprobó una nueva soja transgénica de la firma Syngenta resistente a cuatro familias de herbicidas: glifosato, glufosinato de amonio, 2,4-D e inhibidores de la enzima 4-hidroxifenilpiruvato dioxigenasa (HPPD). Apenas cuatro días después, Naturaleza de Derechos,… Continue reading Denuncian al Estado por transgénicos

While editing the HPPD protein or its expression alone falls short, doing both at once gives strong herbicide tolerance in rice and wheat, pointing to a general way to engineer dosage-sensitive crop t...

La nueva soja que se podrá comercializar en Argentina, desarrollada por Syngenta, contiene tolerancia a glifosato, glufosinato de amonio y 2,4-D, así como a herbicidas inhibidores de la enzima 4-hidroxifenilpiruvato dioxigenasa (HPPD).

Key Points The FDA granted Orphan Drug Designation to vTv Therapeutics’ HPPD for sickle cell disease. HPPD, also known as HPP8668, is an investigation

The oral drug remains investigational; cadisegliatin stays the lead program.

vTv Therapeutics (Nasdaq: VTVT) received FDA Orphan Drug Designation for HPPD, its investigational oral treatment for sickle cell disease.Preclinical studies at Augusta University used the Townes sickle cell disease mouse model. HPPD was orally active and well tolerated, increased fetal hemoglobin, and reduced oxidative stress and red blood cell sickling. Fetal hemoglobin increases were time- and dose-dependent, with effects comparable to or exceeding hydroxyurea, the current standard fetal hemoglobin-inducing therapy.vTv said the designation supports partnering discussions for HPPD while it continues to prioritize cadisegliatin, its lead late-stage type 1 diabetes program. HPPD remains investigational; its safety and efficacy have not been established, and approval or commercial availability is not guaranteed.

Reported Wednesday, Oct 7 - 4:02pm EDT (TheFly subscription required to read more.)

Published in Environmental research

YouTube video by Small Faces - Topic

YouTube video by Small Faces - Topic